Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Mehta, Nehal N. [2 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, M. Alan [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15960
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [1] Effect of metabolic syndrome on efficacy and safety in patients with psoriasis treated with etanercept or tildrakizumab: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Gottlieb, Alice B.
    Mehta, Nehal N.
    Lebwohl, Mark
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB50 - AB50
  • [2] Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 519 - 522
  • [3] Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2
    Fernandez, A. P.
    Dauden, E.
    Gerdes, S.
    Lebwohl, M. G.
    Menter, M. A.
    Leonardi, C. L.
    Gooderham, M.
    Gebauer, K.
    Tada, Y.
    Lacour, J. P.
    Bianchi, L.
    Egeberg, A.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Mehta, N. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : 1774 - 1783
  • [4] The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
    Menter, M. Alan
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Leonardi, Craig
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 703 - 708
  • [5] Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 398 - 407
  • [6] The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: Post hoc analysis of 2 phase 3 trials (reSURFACE 1 and reSURFACE 2)
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Leonardi, Craig
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Myers, Jill
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB131 - AB131
  • [7] EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND RESURFACE 2
    Gottlieb, A. B.
    Mehta, N.
    Menter, A.
    Mendelsohn, A. M.
    Rozzo, S.
    Lebwohl, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1304 - 1305
  • [8] Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
  • [9] Relationship of serum glucose to efficacy and safety of tildrakizumab treatment for psoriasis in patients with and without metabolic syndrome from reSURFACE 1 and reSURFACE 2
    Lebwohl, Mark G.
    Menter, Alan
    Rozzo, Stephen J.
    Parno, Jeff
    Mendelsohn, Alan M.
    Mehta, Nehal N.
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB163 - AB163
  • [10] Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
    van de Kerkhof, Peter C.
    Dauden, Esteban
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB120 - AB120
12345